46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany
The development of compounds that directly target hepatitis C virus (direct acting antivirals or DAAs), used with and without pegylated interferon (PEG-IFN) and ribavirin is moving rapidly and with a burgeoning pipeline.
The following report is an edited summary of a rapid summary from Jules Levin whose natap.org website posted numerous studies from this meeting.
Abstracts from the oral and poster sessions are available online at the following links:
A limited number of web casts are due to be posted online but were not yet available when HTB went to press.